SCHEMBL25758501

SCHEMBL25758501

COc1c(N)ncc2cnn(C3CC3)c12

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 1/20 0.36
ALOX15 P16050 1/20 0.34
NEK2 P51955 3/20 0.34
LRRK2 Q5S007 1/20 0.32
PLK1 P53350 1/20 0.32
NEK1 Q96PY6 1/20 0.32
MAP3K12 Q12852 2/20 0.32
MAP3K11 Q16584 1/20 0.31
PIK3CD O00329 3/20 0.31
ALOX5AP P20292 1/20 0.31
FEN1 P39748 1/20 0.31
FYN P06241 1/20 0.31
AURKA O14965 1/20 0.30
KDR P35968 1/20 0.30
AURKB Q96GD4 1/20 0.30
USP1 O94782 1/20 0.30
MEN1 O00255 1/20 0.30
ALDH1A1 P00352 1/20 0.30
CYP1A2 P05177 1/20 0.30
KMT2A Q03164 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30498234 1.00 FLT3 (0.36) FLT3ALOX15NEK2LRRK2PLK1
SCHEMBL25758499 0.82 PDE4D (0.34) FLT3LRRK2USP1MEN1ALDH1A1
SCHEMBL25240498 0.79 FLT3 (0.38) FLT3ALOX15MAP3K11PIK3CDKDR
Hydrochloric Acid SCHEMBL25239094 0.78 FLT3 (0.38) FLT3ALOX15MAP3K11PIK3CDKDR
SCHEMBL25240549 0.73 LRRK2 (0.36) FLT3LRRK2PIK3CDALOX5APFEN1
SCHEMBL30498401 0.73 FYN (0.32) FYN
SCHEMBL25758213 0.73 HASPIN (0.40) FYNMEN1ALDH1A1KMT2AHSD17B10
SCHEMBL30498340 0.73 HASPIN (0.40) FYNMEN1ALDH1A1KMT2AHSD17B10
SCHEMBL30498066 0.71 PIK3CD (0.41) PIK3CD
SCHEMBL25753092 0.71 PIK3CD (0.41) PIK3CD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250115597-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO LTD (CN) 2025-04-10 US disclosed
US-12129250-B2 TYK2 inhibitors and compositions and methods thereof LYNK PHARMACEUTICALS CO. LTD. (CN) 2024-10-29 US disclosed
US-20240124448-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO. LTD. (CN) 2024-04-18 US disclosed
WO-2023109954-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO. LTD. (CN) 2023-06-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240124448-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF TYK2, JAK2, JAK1 FLT3 119/4885ALOX15 3698/4885NEK2 48/4885
US-20250115597-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF TYK2, JAK2, JAK1 FLT3 119/4885ALOX15 3698/4885NEK2 48/4885
US-12129250-B2 TYK2 inhibitors and compositions and methods thereof TYK2, JAK2, JAK1 FLT3 119/4885ALOX15 3698/4885NEK2 48/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.